Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab–Chemotherapy: A Real-World Study from Serbia.
Simple Summary: Pembrolizumab combined with platinum-based chemotherapy is the standard first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer (NSCLC) and intermediate PD-L1 expression (1–49%). However, treatment outcomes in routine clinical practice remain heterog...
| Publicado en: | Current Oncology Vol. 33; no. 5; pp. 267 - 281 |
|---|---|
| Autores principales: | , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
May2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |